Sanofi Holds Its Ground On Genzyme Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.